Reta glucagon-like peptide-1 (GLP-1) receptor agonists provide a groundbreaking method to diabetes management. These innovative therapies function by mimicking the physiological actions of GLP-1, a hormone produced by the gut in response to meals. By triggering GLP-1 receptors in the pancreas, these compounds boost insulin secretion and inhibit glu

The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual mode agonists targeting the GLP-1 and GIP receptors. While sharing a similar therapeutic goal – improving glycemic control and promoting considerable weight reduction – they exhibit intriguing differences in the